April 17, 2015

To whom it may concern

Nanocarrier Co., Ltd.
Ichiro Nakatomi, Ph.D., President & CEO
(Code No. 4571 Tokyo Stock Exchange Mothers Section)

NanoCarrier to Present at the American Association for Cancer Research (AACR) Annual Meeting

On April 22, 2015, NanoCarrier will present the results of the research on its next-generation technology named Antibody/Drug Conjugated Micelle (ADCM) at the American Association for Cancer Research (AACR) Annual Meeting, one of the largest cancer research conferences in the United States, to be held in Philadelphia from April 18 to April 22, 2015.

In recent years, many companies have begun participating in the development of Antibody Drug Conjugates (ADC) in the field of antibody medicines. However, in view of significant limits on the antibodies and drugs that can be used, there are expectations for the further development of next-generation technology in this area. NanoCarrier has developed new technology that makes it possible to eliminate the demerits of ADC through the development of Antibody/Drug Conjugated Micelle (ADCM), which combines antibodies with micellar nanoparticles.

Among the subjects of this presentation will be an ADCM form of E7974, which NanoCarrier is developing. Compared with the drug alone, the use of antibodies offers more selective delivery to cancer cells, providing a high antitumor effect through the efficient use of the drug, and reducing damage to normal cells, which is said to cause side effects. As a result, this new anticancer agent may be expected to significantly improve the therapeutic index of drugs, and enhance patients’ quality of life (QOL) while in therapy. NanoCarrier is preparing to begin clinical development, and aims to begin clinical trials within two years.

Alongside the in-house development of ADCM, NanoCarrier is also pursuing joint research with pharmaceutical companies and research institutions worldwide. With our proactive stance toward research and development, we will strive to develop revolutionary new next-generation pharmaceuticals.

For Reference: Outline of the Presentation

Recently, we have developed an Antibody/Drug Conjugated Micelle (ADCM) system that makes active targeting a viable anticancer therapy. In this study, monoclonal antibody, trastuzumab or cetuximab, and anticancer drug, anthracycline antibiotic epirubicin or novel hemiasterlin analogue E7974, were used as a targeting sensor and a payload of the ADCM, respectively. The ADCMs showed similar cell-binding behavior and antigen affinity to the original antibodies, and the therapeutic indexes were significantly improved in terms of the maximum tolerated dose/ED50 (50% effective dose) compared to untargeted micelles and native payloads.

Title: Antibody/drug-conjugated micelle as a versatile platform technology for targeted tumor delivery
Authors: Mitsunori Harada, Masami Tsuchiya, Ryusuke Miyazaki, Ryosuke Tanaka, Yu Ito, Kenichiro Naito
Abstract number: 5525

Contact: Tetsuhito Matsuyama
CFO and Head of CEO Office
TEL: +81-3-3241-0553
E-mail: info@nanocarrier.co.jp